Ceeable Wins Awards at MedMo16 Medical Startup Competition

    BOSTON, MA, December 09, 2016 /24-7PressRelease/ -- Ceeable, Inc. was selected as the winner of the MedMo16 competition for mobile digital medical technology. Over 175 companies applied to present on stage during the competition and five were selected. The winners receive a venture funding opportunity and in-kind support services.

"We are excited and honored to be chosen by the MedMo16 panel as the winner of the awards for digital medical device technology and product design. The opportunity to present the Ceeable story to a broad audience of passionate medical advocates is invaluable", says Chris Adams CEO.

The Ceeable Visual Field Analyzer (CVFA) is a cloud-based digital platform used to detect and diagnose retinal disease, including glaucoma, diabetic retinopathy and macular degeneration. The CVFA will deliver rapid, accurate and low-cost visual testing to patient populations that may not have access to traditional visual testing services.

Medmo16 Mega Crowd Challenge is an Equity Crowd Challenge for medical startups. Companies are chosen from a pool of 175 applicants and five are selected. The Crowd Challenge selection process relies on expert judges, and the Medstartr crowd community. Engagement on MedStartr means liking, following, and sharing the projects, as well as offering to try for yourselves or a loved one, adopting the new idea for your patients, piloting it in your clinic or hospital, partnering with your company, or investing in the company. Companies that engage patients, providers, partners, institutions, and investors create a wave of momentum that helps them succeed over 40 times more often than those that don't.

About Ceeable
Ceeable is a leader in digital mobile health for ophthalmology. The Ceeable Visual Field Analyzer (CVFA) is a cloud-based digital platform used to detect and diagnose retinal disease. There are more that 300 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease will reduce healthcare systems costs and help to prevent blindness.

# # #